 ROCKAWAY, N.J., Jan. 21, 2021 GLOBE NEWSWIRE -- electroCore, Inc. Nasdaq: ECOR, a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland HIS has published a Scottish Health Technology Group SHTG adaptation for NHS Scotland on the use of gammaCore for cluster headache. The SHTG publication is based on guidance produced in 2019 by the U.K. National Institute for Health and Care Excellence NICE, which states that gammaCore, when used alongside standard of care, can reduce the frequency and intensity of cluster headache attacks, leading to significant quality of life benefits for people living with this condition and can save an average of 450 per patient in the first year of treatment through a reduction in acute rescue medication use, and with electroCore offering no-cost evaluations for all patients. The SHTG publication recommends that gammaCore should be available for a 3-month trial period for use in treating NHS Scotland patients suffering from cluster headache and the SHTG adaptation will now be disseminated across NHS Scotland health boards by HIS, to inform the use of gammaCore for cluster headache. 